• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Technology Bio Tech

Vaccine Turmoil Won’t Derail Recovery — Social Factors of New Money

Like 0

By Lachlann Tierney, Wednesday, 14 April 2021

In today’s Money Morning…known knowns: we have effective vaccines…known unknowns: virus variants will emerge…unknown unknowns: social factors of ‘new money’…and more…

In today’s Money Morning…known knowns: we have effective vaccines…known unknowns: virus variants will emerge…unknown unknowns: social factors of ‘new money’…and more…

Follow The Money Morning Podcast on Spotify here and on Apple Podcasts here.

In today’s episode of The Money Morning Podcast I speak with Paul Hyslop of Zoono Group Ltd [ASX:ZNO] about their COVID-19-killing products, and the big partnerships they’ve struck up with major companies at home and abroad.

With two major vaccines threatening to go the way of the scrap heap due to blood clot concerns, various doom mongers would be licking their lips at the prospect of being right about the sky falling.

I’ll push back against that today and also give you a look at what I think comes next.

First though, a word about human perception of risk.

You see, the Johnson & Johnson vaccine rollout in the US was recently paused after six people under the age of 50 developed rare blood clot conditions after receiving the jab.

This out of seven million administered doses.

In Reuters’s coverage, experts likened the risk to being struck by lightning in the UK and the risk of oral contraceptives.

From a strictly consequentialist perspective then, one that seeks the best outcomes for the most people, this is an acceptable level of risk.

But from an individual’s perspective — the thought is, ‘what if it were to happen to me?’

The perception of risk and risk appetite go hand in hand for investors, one informs the other.

A large company haemorrhaging cash will usually slide down the charts, as investors can see the risk.

But what about risks we can’t see?

US Secretary of Defense Donald Rumsfeld once notoriously said in a press conference:

‘[T]here are known knowns; there are things we know we know. We also know there are known unknowns; that is to say we know there are some things we do not know. But there are also unknown unknowns—the ones we don’t know we don’t know.’

It’s the ‘unknown unknowns’ that really worry investors.

So, in three sections, I’ll break down my thesis that vaccine turmoil won’t derail the recovery.

Stay up to date with the latest investment trends and opportunities. Click here to learn more.

Known knowns: we have effective vaccines

Not all vaccines are the same.

Some are more effective than others.

The two leading candidates going at the moment are the Moderna and Pfizer/BioNTech vaccines.

And these are the two the US is relying on the most as you can see below:


US COVID 19 Vaccine

Source: Reuters

[Click to open in a new window]

I think the aggressive vaccine rollout in the US is tracking relatively well for a nation of its size.

Both the Moderna and Pfizer/BioNTech vaccines rely on the same technology.

As a result of this technology, they can be chopped and changed reasonably quickly to adapt to what I would call known unknowns — virus variants.

This is not blind cheerleading for mRNA-based vaccines — but more so restrained optimism that the synthetic biology approach to medicine will be a sustained part of our society in this century.

Known unknowns: virus variants will emerge

You’ve likely heard about the UK and South African variants.

And new, nastier variants are likely to emerge if past history is anything to go by.

My concern is that in rushing to secure the bulk of vaccines for their countries, developed countries could eventually shoot themselves in the foot.

Altruism dies in a crisis.

As in, the developing world will see one of these variants emerge, and in turn, emerging markets go down the drain.

Leading to increased risks to those financial institutions exposed to their growth.

You can see hints of the risk on the chart below:


Emerging Market Stocks

Source: Financial Times

[Click to open in a new window]

Lazard Asset Management has this to say on how these countries are faring:

‘The vaccine rollout in developing countries should improve as these countries acquire more supply in the second half of this year. COVAX, a global initiative led by the World Health Organization (WHO) and the GAVI Alliance, has committed to distributing a group of vaccines equitably among developed and developing countries, with the goal of supplying 2 billion doses (vaccinating 1 billion people) by the end of 2021. It began distributing vaccines in late February in Africa and despite some delays in manufacturing and exports, delivered some 31 million doses by late March.’

But should those economies suffer from future variants, and their debt unwind — there could be some danger in this part of the market muddying the waters.

What about the ultimate question mark though?

Unknown unknowns: social factors of ‘new money’

This domain of our knowledge/ignorance is the specialty of Nassim Nicholas Taleb.

He said in Fooled by Randomness:

‘It was confidently believed that the scientific successes of the industrial revolution could be carried through into the social sciences, particularly with such movements as Marxism. Pseudoscience came with a collection of idealistic nerds who tried to create a tailor-made society, the epitome of which is the central planner. Economics was the most likely candidate for such use of science; you can disguise charlatanism under the weight of equations, and nobody can catch you since there is no such thing as a controlled experiment.’

And herein lies the problem.

We’ve printed a bucket load of money, inflated asset prices while turning people away from fiat and towards crypto in one fell swoop.

Where do we go from here? Does society answer the siren song of central bank backed digital currencies (CBDCs)?

I’m sure this ‘new money’ will come with assurances that it is worthy of confidence and designed by the brightest minds — economists no doubt.

But will it be trusted?

These are just some of the impossible question marks hovering over the current vaccine driven recovery.

For now, don’t panic, I’d say.

Just because J&J and AstraZeneca are being shown the door doesn’t mean all is lost.

It’s what comes next that you should really be watching out for.

The re-remaking of what money is.

Regards,

Lachlann Tierney Signature

Lachlann Tierney,
For Money Morning

P.S: Promising Small-Cap Stocks: Market expert Ryan Clarkson-Ledward reveals why these four undervalued stocks could potentially soar in 2021. Click here to learn more.

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Lachlann Tierney

Lachlann’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • From geek to God: the trillion dollar maven
    By Callum Newman

    Here’s a few things I discovered this month after reading The Thinking Machine: Jensen Huang, Nvidia, and the World’s Most Coveted Microchip. If you want to be a billionaire, have a read of this!

  • The stock market prices in peace in the Middle East
    By Brian Chu

    Will the conflict between Israel and Iran escalate? Today, I present my views on why it could de-escalate sooner than many are made to believe.

  • Ignore the bores and the bears: some shares are going gangbusters
    By Callum Newman

    All year you and I have been on a mission. It’s to discover if now is the time to be upping your exposure to risk assets, or dialling it down. I put my stake in the ground ages ago: get bullish! It’s working.

Primary Sidebar

Latest Articles

  • From geek to God: the trillion dollar maven
  • The stock market prices in peace in the Middle East
  • Ignore the bores and the bears: some shares are going gangbusters
  • The Perfect Marriage: Combining Fundamental AND Technical Analysis
  • Your best chance to be in the top 10% will come from here

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988